Impairment Oriented Versus Task Oriented Gait Training In Transfemoral Amputee Rehabilitation.

May 4, 2026 updated by: Foundation University Islamabad
This study examines the comparison between Impairment Oriented versus Task Oriented Gait Training in Transfemoral Amputee Rehabilitation. A randomized controlled trial conducted with 40 participants divided into two groups .Both groups receive pre-gait training and corrective walking exercises for 10 days .

Study Overview

Detailed Description

Participants were randomly assigned into two groups. Group A ,which focus on strengthening exercises such as ,side lying hip abductor strengthening ,prone lying hip extensors strengthening ,supine lying hip flexors strengthening ,side lying hip adductors strengthening and bridging .Each exercise should be hold for 10-20 seconds with 10 repetition .

Group B , which prioritise functional activities and real life task such as lateral trunk bending with crossed leg ,stepping over obstacle ,lateral step ups ,walk with visual markers on floor,sit to stand focus on glutes activation .

Corrective exercises will be performed by both groups . Outcome measures include spatiotemporal parameters and Amputee Mobility Predictor (AMP).

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Punjab Province
      • Islamabad, Punjab Province, Pakistan, 46000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age 18-40 years
  • Unilateral transfemoral amputees
  • Cleared by physicians for participation in physical therapy
  • Willing

Exclusion Criteria:

  • Residual limb complication that interfere with mobility
  • History of neurological disorders
  • Any joint complication in intact limb
  • Currently enrolled in another research study
  • Mild to severe cognitive impairment (MoCA) i.e , score less than 25 , Uncontrolled diabetes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Impairment oriented group A

Group A will receive :

  1. Warm up
  2. Impairement oriented training
  3. Cool down

Participants will receive ten days training programs with 5 days in each week. Each session will include warm up followed by sit to stand , stand to sit, walking in parallel bars ,ascend and descend stairs.

Participants with group A will receive strengthening exercises of hip flexor , abductors, adductors and bridging of 10 repetition with 10-20 second hold according to patient.

Experimental: Task oriented group B

Group B will receive :

  1. Warm up
  2. Task oriented training
  3. Cool down

Participants will receive ten days training programs with 5 days in each week. Each session will include warm up followed by sit to stand , stand to sit, walking in parallel bars ,ascend and descend stairs.

Participants with group B will receive lateral trunk bending, stepping over obstacle, lateral step ups, walk with visual markers on floor, sit to stand focus on glutes activation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Amputee Mobility Predictor (AMP)
Time Frame: on 3rd and 10th day.
AMP is functional scale utilising a 3 point rating scale of 0-2.AMP scores have been correlated with functional medicare classification levels of 0-4.
on 3rd and 10th day.
Gait speed
Time Frame: on 3rd and 10th day of treatment
Gait speed in meters per second , measured with 10 meter walking test, gait speed computed by dividing distance covered by time taken to cover it . (m/s)
on 3rd and 10th day of treatment
cadence
Time Frame: On the 3rd day of treatment and 10th day of treatment
The number of steps taken per minute during walking, measured in steps per minute (steps/min )
On the 3rd day of treatment and 10th day of treatment
Cycle time
Time Frame: On the 3rd day of treatment and 10th day of treatment
The time required to complete one full gait cycle from the initial contact of one foot to the next initial contact of same foot, measured in seconds (s)
On the 3rd day of treatment and 10th day of treatment
Stride length
Time Frame: On the 3rd day of treatment and 10th day of treatment
Distance between two consecutive heel strikes of same foot , measures in meter (m)
On the 3rd day of treatment and 10th day of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Saliha Bibi, DPT, Foundation University Islamabad

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 6, 2026

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

July 15, 2026

Study Registration Dates

First Submitted

April 15, 2026

First Submitted That Met QC Criteria

May 4, 2026

First Posted (Actual)

May 11, 2026

Study Record Updates

Last Update Posted (Actual)

May 11, 2026

Last Update Submitted That Met QC Criteria

May 4, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • FUI/FUCP/CTR/07.26/SalihaBibi

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Transfemoral Amputees

Clinical Trials on Impairment oriented (Group A)

Subscribe